Researchers reverse juvenile diabetes in animal model; Clinical trial FDA approvedMarch 28, 2006Groundbreaking human clinical trial for type 1 diabetes to start this spring in Pittsburgh - Children's Hospital of Pittsburgh of UPMC researchers reverse juvenile diabetes in animal model; Phase 1 clinical trial approved by FDA. Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center researchers Massimo Trucco, MD, and Nick Giannoukakis, PhD, observed marked amelioration of diabetes in a mouse model by a novel treatment strategy involving specific modification of the animal's own dendritic cells, thereby reversing diabetes in animal studies. The U.S. Food and Drug Administration (FDA) approved the start of a clinical trial to evaluate the safety and feasibility of the treatment (Phase 1 trial). The trial is expected to begin sometime this spring and will include at least 15 patients over the age of 18, with type 1 diabetes. Dr. Trucco, director of the Division of Immunogenetics at Children's, and his research team will collaborate with Theresa Whiteside, PhD, scientific director at the University of Pittsburgh Cancer Institute. Dr. Trucco and his team found that by removing dendritic cells from the blood during a two- to four-hour procedure, some 20 million dendritic cells can be harvested. Dendritic cells are cells found in the bloodstream and normally function as one of nature's most efficient immune function cells. The cells identify foreign substances such as cancer cells, process these foreign substances, and then jumpstart the immune response by bringing these foreign substances to the attention of T cells. Once harvested, researchers then combine the dendritic cells with specific blockers of molecules, known as CD40, CD80 and CD86, all of which can be synthesized in a laboratory. This treatment strategy was found to inhibit the interaction and destructive effect of T cells on the insulin-producing beta cells of the pancreas, a process that is known to be a critical part of how diabetes occurs. Subcutaneous injection of dendritic cells into the abdominal/pelvic area near the pancreas and lymph nodes, blocks the T cells as they travel to the pancreas to destroy beta cells. "We did this in mice, giving them six injections over the course of several weeks. The injections interrupted the T cell and beta cell interaction, allowing the beta cells in the pancreas to regenerate. This enabled the pancreas of the mice to begin producing insulin again," said Dr. Trucco, who also is the Hillman Professor of Pediatric Immunology at Children's Hospital and a professor of Pediatrics at the University of Pittsburgh School of Medicine. "The injections proved capable of stopping this vicious cycle, and through this process curing type 1 diabetes in a mouse." Until now, scientists weren't sure why the immune system attacks the beta cells, but the result is that the body stops producing insulin. When that happens, glucose builds up in the blood, but the body's cells starve to death. "We are very excited to begin the clinical trials and see if this process will work in patients with type 1 diabetes," said Dr. Trucco. "A type 1 diabetes diagnosis can be devastating for children and their families. We hope this trial will have results that are life-altering for patients who suffer from this disease." In addition, Dr. Trucco and his team want to combine the dendritic cells with small portions (i.e. peptides) of insulin. Dr. Trucco believes that adding small doses of insulin to the dendritic cells will help guide the dendritic cells directly to the T cells. Adding the insulin ensures the dendritic cells are used specifically to block the T cell destruction of the beta cells, and not otherwise interrupt a person's immunity. In other words, the dendritic cells are led directly to the target, the T cells that are causing the malfunction of the pancreas, and not to another part of the body. Type 1 diabetes also is known as insulin-dependent diabetes mellitus (IDDM) or juvenile-onset diabetes. While type 2 diabetes typically strikes adults, the National Institutes of Health (NIH) reports that more than 1 million children and teenagers (age 19 and younger) have type 1 diabetes. According to the NIH, 5 percent to 10 percent of diagnosed diabetes cases in the United States are type 1 diabetes. Type 1 diabetes is regarded as an autoimmune disease because a person's immune system attacks and destroys the beta cells in the pancreas that produce insulin. Symptoms of type 1 diabetes usually develop over a short period of time and include increased thirst, frequent urination, constant hunger, weight loss, blurred vision and extreme fatigue. People with type 1 diabetes require numerous daily injections of insulin to survive. About Dr. Trucco Massimo Trucco, MD, has dedicated his life's work to finding a cure for diabetes - finding a cure is a personal quest for him. As an international leader in the field of immunogenetics, Dr. Trucco has pioneered numerous important studies and also maintains a federally funded national bone marrow HLA typing center within his lab. With this funding, Dr. Trucco and his team are able to continue their landmark research into improving the prediction of type 1 diabetes and understanding and managing its complications. Building on his discovery in 1994 that type 1 diabetes susceptibility may be genetic in nature and triggered by viruses, Dr. Trucco's discoveries have continue to lead to better processes for molecular typing for matching bone marrow donors and recipients, the ability to identify those at risk for diabetes, an understanding of the link between a common virus and type 1 diabetes, and a potential cure for the pancreatic damage that causes insulin dependence. Diabetes and children statistics: - The risk of developing type 1 diabetes is higher than virtually all other severe chronic diseases of childhood. - Peak incidence occurs during puberty, around 10 to 12 years of age in girls, and around 12 to 14 years of age in boys. - The symptoms of type 1 diabetes can resemble the flu in children. - Type 1 diabetes tends to run in families. Brothers and sisters of children with type 1 diabetes have about a 10 percent chance of developing the disease by age 50. - The identical twin of a person with type 1 diabetes has a 25 percent to 50 percent chance of developing type 1 diabetes. Children's Hospital of Pittsburgh |
|||||||||||||||||||||
| Related Juvenile Diabetes Current Events and Juvenile Diabetes News Articles Children with autism show slower pupil responses, MU study finds Autism affects 1 in 150 children today, making it more common than childhood cancer, juvenile diabetes and pediatric AIDS combined. Protein critical for insulin secretion may be contributor to diabetes A cellular protein from a family involved in several human diseases is crucial for the proper production and release of insulin, new research has found, suggesting that the protein might play a role in diabetes. JDRF-funded studies show regular CGM use increases diabetes control for all age groups The latest data from groundbreaking human clinical trials of the effectiveness of continuous glucose monitors (CGM) show that the primary determinant of improvements in achieving better diabetes control is regular use of monitors - six days per week or more - rather than the age of patients, and that benefits continue well past the time when people with type 1 diabetes begin using the devices - including experiencing fewer low blood sugar emergencies. Taking the Needle's Sting Out of Diabetes Found in 30% of all human cancer tumors, the Ras protein literally "drives cells crazy," says Prof. Yoel Kloog, the dean of the Faculty of Life Sciences at Tel Aviv University. Prof. Kloog was the first in the world to develop an effective anti-Ras drug against pancreatic cancer, currently in clinical trials. Noninsulin-producing alpha cells in the pancreas can be converted to insulin-producing beta cells In findings that add to the prospects of regenerating insulin-producing cells in people with type 1 diabetes, researchers in Europe -- co-funded by the Juvenile Diabetes Research Foundation -- have shown that insulin-producing beta cells can be derived from non-insulin-producing cells in the pancreas. UT researcher: Interferon alpha can delay full onset of type I diabetes A low dose of oral interferon alpha shows promise in preserving beta cell function for patients with newly diagnosed type 1 diabetes, or juvenile diabetes. Triglycerides implicated in diabetes nerve loss A common blood test for triglycerides - a well-known cardiovascular disease risk factor - may also for the first time allow doctors to predict which patients with diabetes are more likely to develop the serious, common complication of neuropathy. Narcolepsy is an autoimmune disorder, Stanford researcher says Ten years ago, Stanford University School of Medicine scientist Emmanuel Mignot, MD, PhD, and his colleagues made headlines when they identified the culprit behind the sleep disorder narcolepsy. Potential preventative therapy for Type 1 diabetes Scientists believe they may have found a preventative therapy for Type 1 diabetes, by making the body's killer immune cells tolerate the insulin-producing cells they would normally attack and destroy, prior to disease onset. Human stem cells promote healing of diabetic ulcers Treatment of chronic wounds is a continuing clinical problem and socio-economic burden with diabetic foot ulcers alone costing the NHS £300 million a year. More Juvenile Diabetes Current Events and Juvenile Diabetes News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||